These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 32998272

  • 21. Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients.
    Song J, Chen X, Zhou L, Yu W, Liu H, Yuan F.
    J Int Med Res; 2023 Oct; 51(10):3000605231204475. PubMed ID: 37843847
    [Abstract] [Full Text] [Related]

  • 22. Hypoxia-inducible factor prolyl hydroxylase domain inhibitor may maintain hemoglobin synthesis at lower serum ferritin and transferrin saturation levels than darbepoetin alfa.
    Ogawa C, Tsuchiya K, Tomosugi N, Maeda K.
    PLoS One; 2021 Oct; 16(6):e0252439. PubMed ID: 34143801
    [Abstract] [Full Text] [Related]

  • 23. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
    Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, Tao Y, Liang X, Liu Z, Xing C, Chen J, Luo L, Zuo L, Liao Y, Liu BC, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP.
    N Engl J Med; 2019 Sep 12; 381(11):1001-1010. PubMed ID: 31340089
    [Abstract] [Full Text] [Related]

  • 24. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
    Akizawa T, Macdougall IC, Berns JS, Yamamoto H, Taguchi M, Iekushi K, Bernhardt T.
    Nephron; 2019 Sep 12; 143(4):243-254. PubMed ID: 31387097
    [Abstract] [Full Text] [Related]

  • 25. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
    Yoshida T, Hayashi M.
    Keio J Med; 2017 Sep 26; 66(3):44-50. PubMed ID: 27990008
    [Abstract] [Full Text] [Related]

  • 26. Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study.
    Donck J, Gonzalez-Tabares L, Chanliau J, Martin H, Stamatelou K, Manamley N, Farouk M, Addison J.
    Adv Ther; 2014 Nov 26; 31(11):1155-68. PubMed ID: 25367412
    [Abstract] [Full Text] [Related]

  • 27. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
    Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, Leong R, Hemmerich S, Yu KH, Neff TB.
    Nephrol Dial Transplant; 2015 Oct 26; 30(10):1665-73. PubMed ID: 26238121
    [Abstract] [Full Text] [Related]

  • 28. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
    Singh AK, Carroll K, Perkovic V, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Więcek A, Blackorby A, Cizman B, Cobitz AR, Davies R, Dole J, Kler L, Meadowcroft AM, Zhu X, McMurray JJV, ASCEND-D Study Group.
    N Engl J Med; 2021 Dec 16; 385(25):2325-2335. PubMed ID: 34739194
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.
    Kawai T, Kusano Y, Yamada K, Ueda C, Kawai A, Masaki T.
    J Artif Organs; 2019 Jun 16; 22(2):146-153. PubMed ID: 30426250
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
    Eckardt KU, Agarwal R, Aswad A, Awad A, Block GA, Bacci MR, Farag YMK, Fishbane S, Hubert H, Jardine A, Khawaja Z, Koury MJ, Maroni BJ, Matsushita K, McCullough PA, Lewis EF, Luo W, Parfrey PS, Pergola P, Sarnak MJ, Spinowitz B, Tumlin J, Vargo DL, Walters KA, Winkelmayer WC, Wittes J, Zwiech R, Chertow GM.
    N Engl J Med; 2021 Apr 29; 384(17):1601-1612. PubMed ID: 33913638
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy.
    Bhandari S, Norfolk D, Brownjohn A, Turney J.
    Am J Kidney Dis; 1997 Dec 29; 30(6):814-21. PubMed ID: 9398126
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.
    Ther Apher Dial; 2010 Jun 29; 14(3):240-75. PubMed ID: 20609178
    [Abstract] [Full Text] [Related]

  • 40. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
    Chertow GM, Pergola PE, Farag YMK, Agarwal R, Arnold S, Bako G, Block GA, Burke S, Castillo FP, Jardine AG, Khawaja Z, Koury MJ, Lewis EF, Lin T, Luo W, Maroni BJ, Matsushita K, McCullough PA, Parfrey PS, Roy-Chaudhury P, Sarnak MJ, Sharma A, Spinowitz B, Tseng C, Tumlin J, Vargo DL, Walters KA, Winkelmayer WC, Wittes J, Eckardt KU, PRO2TECT Study Group.
    N Engl J Med; 2021 Apr 29; 384(17):1589-1600. PubMed ID: 33913637
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.